Major objective of work is in-vitro cytotoxicity assay of newly synthesized compounds and estimated deaths due to the cancer in human beings in US. Current manuscript also provides the chemotherapy of cancer with highly active and safe anti-cancer synthesized quinoxaline compounds and their in-vitro assay at National Cancer Institute (NCI). A series of new quinoxaline derivatives 3 (a-h) has been prepared. The newly synthesized compounds were further evaluated in the National Cancer Institute for their in-vitro cytotoxicity assay. Among them compound 3h has been show highest activity against Leukemia RPMI-8226 cell lines (GI 50 : 1.11 μM) as compared to other tested compounds. It is to be noted that compound 3e has been show significant activity against cancer cell lines. (GI 50 : 1.11 μM). We conclude that the ongoing studies of targeted agents in conjunction with chemotherapy will show whether there are alternative option for new and safer medicine for cancer in future as well as opens the new doors in era of cancer research. .
INTRODUCTION
Cancer is a major public health problem in the United States and many other parts of the world. Currently, one in four deaths in the United States is due to the cancer. In given manuscript, we provides the expected numbers of new cancer cases and deaths in 2011, as well as an overview of some new synthetic quinoxaline compounds and its anticancer activity. Table 1 has been show the expected number of deaths from cancer projected for 2011 for men, women, and both sexes combined. It is estimated that about 571,950 Americans will die from cancer, corresponding to more than 1500 deaths per day. Cancers of the lung, bronchus, prostate, colorectum in men and cancers of the lung, bronchus, breast and colorectum in womens continue to be the most common causes of death (Siegel, Ward, Brawley, Jemal, 2006) . So it's a moral responsibility of every budding researcher's to go for a development of a new and safer anticancer drugs which can be save the life of maximum in future. On the behalf of a social benefit we provides the expected numbers of new synthesized quinoxaline compounds as well as their glamorous anticancer activity against 60 cell line panel under the Developmental Therapeutic Programme (DTP) at National Cancer Institute (NCI, USA), by keeping in mind that the medicinal importance of quinoxaline moiety and its contribution to this era of research give a ray of hope to the patients suffering from cancer worldwide. 
Table1. Estimated New Cancer Cases and Deaths by

RESULTS AND DISCUSSION
A series of new quinoxaline derivatives 3 (a-h) has been prepared. The newly synthesized compounds 3a, 3b, 3c, 3d, 3e, 3f, 3g and 3h were further evaluated in the National Cancer Institute for in-vitro cytotoxicity assay. Among them compound 3e has been show highest activity against Leukemia RPMI-8226 cell lines (GI 50 : 1.11 μM) as compared to other tested compounds. It is to be noted that compound 3h has been show significant activity against cancer cell lines. (GI 50 : 1.11 μM) The synthesis of compounds 3 (a-h) is given in Scheme-1. The derivatives were characterized by spectral studies and confirmed to the structures. The in vitro anticancer screening at NCI is a two-stage process, beginning with the evaluation of all compounds against the 60 cell lines at a single dose of 10 µM. The output from the single dose screen is reported as a mean graph and is available for analysis by the COMPARE programme. Compounds which exhibit significant growth inhibition are evaluated against the 60 cell panel at five concentration levels as shown in table 2. The human tumor cell lines of the cancer screening panel are grown in RPMI 1640 medium containing 5 % fetal bovine serum and 2 mM L-glutamine. For a typical screening experiment, cells are inoculated into 96 well microtiter plates in 100 µL at plating densities ranging from 5,000 to 40,000 cells/well depending on the doubling time of individual cell lines. After cell inoculation, the microtiter plates are incubated at 37 °C , 5% CO 2 , 95 % air and 100% relative humidity for 24 h prior to addition of experimental drugs. After 24 h, two plates of each cell line are fixed in situ with TCA, to represent a measurement of the cell population for each cell line at the time of drug addition (Tz). Experimental drugs are solubilized in dimethyl sulfoxide at 400 fold the desired final maximum test concentration and stored frozen prior to use. At the time of drug addition, an aliquot of frozen concentrate is thawed and diluted to twice the desired final maximum test concentration with complete medium containing 50 µg/ml gentamycin. Additional four, 10-fold or ½ log serial dilutions are made to provide a total of five drug concentrations plus control. Aliquots of 100 µl of these different drug dilutions are added to the appropriate microtiter wells already containing 100 µl of medium, resulting in the required final drug concentrations.
Following the drug addition, the plates are incubated for an additional 48 h at 37 °C , 5% CO 2 , 95% air, and 100% relative humidity. For adherent cells, the assay is terminated by the addition of cold TCA. Cells are fixed in situ by the gentle addition of 50 µl of cold 50% (w/v) TCA (final concentration, 10% TCA) and incubated for 60 minutes at 4 °C . The supernatant is discarded, and the plates are washed five times with tap water and air dried. Sulforhodamine B (SRB) solution (100 µl) at 0.4% (w/v) in 1% acetic acid is added to each well, and plates are incubated for 10 minutes at room temperature. After staining, unbound dye is removed by washing five times with 1% acetic acid and the plates are air dried. Bound stain is subsequently solubilized with 10 mM trizma base, and the absorbance is read on an automated plate reader at a wavelength of 515 nm. For suspension cells, the methodology is the same except that the assay is terminated by fixing settled cells at the bottom of the wells by gently adding 50 µl of 80% TCA (final concentration, 16% TCA). Using the seven absorbance measurements [time zero, (Tz), control growth, (C), and test growth in the presence of drug at the five concentration levels (Ti)], the percentage growth is calculated at each of the drug concentrations levels. Percentage growth inhibition is calculated as: . Toxicity is measured in terms of lethality; both compounds are not lethal and safe in nature as it is obvious by examining the LC 50 value as shown in Fig. 1 and 4 . were subsequently tested in 5-dose testing mode. These encouraging results of biological screening of the tested compounds could offer an excellent framework in this field that may lead to discovery of potent antitumor agent. We conclude that the ongoing studies of targeted agents in conjunction with chemotherapy will show whether there are alternative option for new and safer medicine for cancer in future which may decline the ongoing incidence of deaths due to the cancer.
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